Literature DB >> 25404148

Glioblastoma heterogeneity and cancer cell plasticity.

Dinorah Friedmann-Morvinski1.   

Abstract

Glioblastoma (GBM) is the most common and malignant type of primary brain tumor. It represents one of the deadliest human cancers, with an average survival at diagnosis of about 1 year. This poor prognosis is due to therapeutic resistance and tumor recurrence after surgical removal. One of the most important hallmarks of GBM is tumor heterogeneity. Intertumor heterogeneity is mostly characterized by distinct genetic alterations that occur in individual tumors originating in the same organ and allows the classification of these tumors into different molecular subtypes. Intratumor heterogeneity-the diversity within individual tumors-has become the focus of research interest in the past few years, and tumor cell plasticity as a new source of cancer stem cells has added another level of complexity to this phenomenon. This review describes the molecular heterogeneity of GBMs at the transcriptome level and the expression profile-based classification of histopathologically indistinguishable tumors into different subtypes. In addition, the role of dedifferentiation of tumor cells into a stem cell-like state is discussed as a source of cellular heterogeneity within tumors, highlighting tumor cell plasticity as an important driver of GBM heterogeneity. Understanding tumor heterogeneity will help design better therapies against GBM and avoid tumor recurrence.

Entities:  

Mesh:

Year:  2014        PMID: 25404148     DOI: 10.1615/critrevoncog.2014011777

Source DB:  PubMed          Journal:  Crit Rev Oncog        ISSN: 0893-9675


  77 in total

Review 1.  Prophylactic anticonvulsants in patients with primary glioblastoma.

Authors:  Arvin R Wali; Robert C Rennert; Sonya G Wang; Clark C Chen
Journal:  J Neurooncol       Date:  2017-07-28       Impact factor: 4.130

2.  Development of a Function-Blocking Antibody Against Fibulin-3 as a Targeted Reagent for Glioblastoma.

Authors:  Mohan S Nandhu; Prajna Behera; Vivek Bhaskaran; Sharon L Longo; Lina M Barrera-Arenas; Sadhak Sengupta; Diego J Rodriguez-Gil; E Antonio Chiocca; Mariano S Viapiano
Journal:  Clin Cancer Res       Date:  2017-11-16       Impact factor: 12.531

3.  GBM-Derived Wnt3a Induces M2-Like Phenotype in Microglial Cells Through Wnt/β-Catenin Signaling.

Authors:  Diana Matias; Luiz Gustavo Dubois; Bruno Pontes; Luciane Rosário; Valeria Pereira Ferrer; Joana Balça-Silva; Anna Carolina Carvalho Fonseca; Lucy Wanjiku Macharia; Luciana Romão; Tania Cristina Leite de Sampaio E Spohr; Leila Chimelli; Paulo Niemeyer Filho; Maria Celeste Lopes; José Garcia Abreu; Flavia Regina Souza Lima; Vivaldo Moura-Neto
Journal:  Mol Neurobiol       Date:  2018-06-14       Impact factor: 5.590

4.  Transferrin-targeted, resveratrol-loaded liposomes for the treatment of glioblastoma.

Authors:  Aditi Jhaveri; Pranali Deshpande; Bhushan Pattni; Vladimir Torchilin
Journal:  J Control Release       Date:  2018-03-06       Impact factor: 9.776

5.  Effect and molecular mechanism of mTOR inhibitor rapamycin on temozolomide-induced autophagic death of U251 glioma cells.

Authors:  Bing Li; Chun Zhou; Liang Yi; Lunshan Xu; Minhui Xu
Journal:  Oncol Lett       Date:  2017-12-06       Impact factor: 2.967

Review 6.  Extracellular Vesicles and MicroRNAs: Their Role in Tumorigenicity and Therapy for Brain Tumors.

Authors:  Agnieszka Bronisz; Jakub Godlewski; E Antonio Chiocca
Journal:  Cell Mol Neurobiol       Date:  2016-03-17       Impact factor: 5.046

7.  Novel approaches for glioblastoma treatment: Focus on tumor heterogeneity, treatment resistance, and computational tools.

Authors:  Silvana Valdebenito; Daniela D'Amico; Eliseo Eugenin
Journal:  Cancer Rep (Hoboken)       Date:  2019-11-11

8.  Diagnostic accuracy of MRI texture analysis for grading gliomas.

Authors:  Austin Ditmer; Bin Zhang; Taimur Shujaat; Andrew Pavlina; Nicholas Luibrand; Mary Gaskill-Shipley; Achala Vagal
Journal:  J Neurooncol       Date:  2018-08-25       Impact factor: 4.130

9.  Comprehensive genomic profiling of glioblastoma tumors, BTICs, and xenografts reveals stability and adaptation to growth environments.

Authors:  Yaoqing Shen; Cameron J Grisdale; Sumaiya A Islam; Pinaki Bose; Jake Lever; Eric Y Zhao; Natalie Grinshtein; Yussanne Ma; Andrew J Mungall; Richard A Moore; Xueqing Lun; Donna L Senger; Stephen M Robbins; Alice Yijun Wang; Julia L MacIsaac; Michael S Kobor; H Artee Luchman; Samuel Weiss; Jennifer A Chan; Michael D Blough; David R Kaplan; J Gregory Cairncross; Marco A Marra; Steven J M Jones
Journal:  Proc Natl Acad Sci U S A       Date:  2019-08-30       Impact factor: 11.205

10.  P32-specific CAR T cells with dual antitumor and antiangiogenic therapeutic potential in gliomas.

Authors:  Liat Rousso-Noori; Ignacio Mastandrea; Shauli Talmor; Tova Waks; Anat Globerson Levin; Maarja Haugas; Tambet Teesalu; Luis Alvarez-Vallina; Zelig Eshhar; Dinorah Friedmann-Morvinski
Journal:  Nat Commun       Date:  2021-06-14       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.